Levosimendan Ameliorates Adverse Pulmonary Vascular Remodeling in Group-2 Pulmonary Hypertension.
Antonella Abi-Sleimen, Ruaa Al‐Qazazi, Yann Grobs, Yahe Xu, Tsukasa Shimauchi, Ashley Y Martin, Danchen Wu, Reem El Kabbout, Manon Mougin, Charlie Théberge, Steeve Provencher, Olivier Boucherat, Sébastien Bonnet, Stephen L. Archer, François Potus
This study develops preclinical models of Group-2 pulmonary hypertension and shows that levosimendan improves cardiac function and reduces pulmonary vascular inflammation and remodeling.
bioRxiv · Oct 23, 2025 · PreprintMolecular Biology